L-Arginine, Vascular Response and Mechanisms

Phase 2

Completed

• Conditions: Hypertension; Diabetes
• Interventions: Dietary Supplement: Placebo Supplement; Dietary Supplement: L-Arginine

• Registration Number: NCT01482247
• Lead Sponsor: Brigham and Women's Hospital

Brief Summary

The purpose of the study is to employ the supplement L-arginine to test the hypothesis that activation of blood flow to the brain during cognitive tasks is regulated by nitric oxide in older subjects with diabetes mellitus and/or hypertension (high blood pressure).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-11-28
• Study First Submitted QC: 2011-11-28
• Study First Posted: 2011-11-30
• Study Start: 2012-04
• Primary Completion: 2014-01
• Study Completion: 2014-01
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-27
• Last Update Posted: 2016-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• diabetes and/or hypertension

Exclusion Criteria

• alzheimers disease, dementia, stroke, active herpes, recent angina or heart attack

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo Supplement	Placebo Supplement	-
L-arginine	L-Arginine	-

Primary Outcome Measures

Name	Time	Method
Functional transcranial doppler measures	6 weeks

Secondary Outcome Measures

Name	Time	Method
Finger Blood Flow - Plethysmography (PAT)	6 weeks
Flow Mediated Dilation (FMD)	6 weeks

Trial Locations

Locations (1)

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States